skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

 

The US Food and Drug Administration says in a new immediately-in-effect guidance that it will temporarily allow limited modifications of medical-use ventilation equipment during the coronavirus public health emergency to bolster supplies of ventilators to treat patients during the coronavirus pandemic.

The FDA also would allow use of anesthesia gas machines, and continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP), to treat COVID-19 patients with respiratory insufficiency, it said in its enforcement policy for ventilators, accessories and other respiratory devices for the COVID-19 crisis.

“FDA does not intend to object to limited modifications … to the hardware or software of agency-cleared ventilators or devices used to support patients with respiratory failure.” – James Lee

The March 22 FDA guidance applies to many different types of ventilators, anesthesia gas machines, oxygen conservers and other devices similar to ventilators – as well as conventional ventilators – and was issued “to help expand the availability of ventilators, as a well as other respiratory devices and their accessories during the pandemic,” the agency wrote.

“FDA does not intend to object to limited modifications … to the hardware or software of agency-cleared ventilators or devices used to support patients with respiratory failure,” FDA device center respiratory assistant director James Lee said in the guidance.

The 13 types of ventilators under the policy, all of which are listed as class II, are:

Device Type

Product Code

Ventilator, continuous, facility use

CBK

Ventilator, continuous, minimal ventilator support, facility use

MNT

Ventilator, continuous, home use

NOU

Ventilator, continuous, minimal ventilator support, home use

NQY

Ventilator, continuous, non-life-supporting

MNS

Mechanical ventilator

ONZ

Ventilator, emergency, powered (resuscitator)

BTL

Gas-machine, anesthesia

BSZ

Ventilator, non-continuous, (respirator) including masks and interfaces under the same product code

BZD

Conserver, oxygen

NFB

Devices, positive pressure breathing, intermittent

NHJ

Resuscitator, manual, non-self-inflating

NHK

High flow/high velocity humidified oxygen delivery device

QAV

Source:Enforcement Policy for Ventilators and Accessories and Other Respiratory Devices during the COVID-19 Public Health Emergency, Guidance for Industry and FDA Staff, March 2020

 

Changes To Ventilator Motor, Tubing OK

In the guidance, FDA provided a couple of examples of the flexibility it would apply to its regulations for ventilator manufacturing. One was changes to the ventilator motor, to let an alternate supplier meet design specifications; another was changes to the ventilator tubing, which would allow more flexible material sourcing.

“We believe this approach will help manufacturers that want to add production lines or manufacture at alternate sites with different manufacturing equipment to increase manufacturing capacity,” the agency wrote. The flexibility should also reduce supply chain interruptions and “manufacturing bottlenecks,” according to the FDA.

American auto giant General Motors Co. announced late on 20 March that it has teamed up with Seattle-based Ventec Life Systems to manufacture much-needed medical ventilators as the US braces for a strained health care system from COVID-19.

The agency also pointed out that use of ventilators outside their cleared environment of use – such as employing a home-use ventilator in a health care facility – would also be permitted. Sleep apnea devices, including CPAP and BiPAP, could also be pressed into service to treat patients with respiratory insufficiency, the agency noted, “as long as appropriate design mitigations are in place to limit aerosolizations.”

The FDA provided a list of modifications to agency-cleared hardware and software that it believes “would not create undue risk,” during the coronavirus public health emergency. A few examples of these modifications include:

  • Modifications to motors, batteries and other electrical components;

  • Material changes to components in the gas pathway or with other patient tissue contact;

  • Introduction of filtration to minimize aerosolization; and

  • Software modifications to modify ventilation parameters including inspiratory pressure, tidal volumes, and flow rates.

The agency said it won’t object to firms making modifications or adding to the hardware/software architectures to allow for increased remote monitoring, such as the addition of wireless or Bluetooth capability.

Read also

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Start a free trial

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now